prochlorperazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2274 58-38-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prochlorperazine mesylate
  • prochlorperazine
  • capazine
  • chlormeprazine
  • chlorperazine
  • meterazin
  • meterazine
  • proazine
  • prochlorpemazine
  • prochlorperazin
  • prochlorpromazine
  • prochlorperazine maleate
  • prochlorperazine edisylate
  • prochlorperazine dimaleate
  • prochlorperzine
A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
  • Molecular weight: 373.94
  • Formula: C20H24ClN3S
  • CLOGP: 4.58
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 9.72
  • ALOGS: -4.53
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
50 mg P
0.10 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.83 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 23, 1956 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nausea 300.53 11.37 1426 45718 686028 45952890
Febrile neutropenia 256.41 11.37 391 46753 94236 46544682
Disease progression 235.77 11.37 369 46775 90931 46547987
Drug ineffective 233.58 11.37 206 46938 677632 45961286
Dehydration 197.50 11.37 472 46672 159068 46479850
Vomiting 175.05 11.37 909 46235 451885 46187033
White blood cell count decreased 168.90 11.37 359 46785 111872 46527046
Diarrhoea 147.91 11.37 1017 46127 558585 46080333
Plasma cell myeloma 142.39 11.37 199 46945 44279 46594639
Fatigue 138.91 11.37 1068 46076 607629 46031289
Platelet count decreased 118.31 11.37 291 46853 99733 46539185
Neutropenia 105.31 11.37 351 46793 142853 46496065
Toxicity to various agents 94.42 11.37 48 47096 211718 46427200
Malignant neoplasm progression 92.19 11.37 203 46941 64723 46574195
Constipation 91.49 11.37 383 46761 173714 46465204
Death 89.46 11.37 612 46532 334936 46303982
Rheumatoid arthritis 88.41 11.37 68 47076 240147 46398771
Asthenia 77.95 11.37 559 46585 310516 46328402
Neutrophil count decreased 68.81 11.37 142 47002 43284 46595634
Contraindicated product administered 67.92 11.37 3 47141 79944 46558974
Heart rate abnormal 64.27 11.37 41 47103 3346 46635572
Decreased appetite 64.24 11.37 374 46770 193462 46445456
Blood magnesium decreased 62.79 11.37 66 47078 10926 46627992
Full blood count decreased 60.33 11.37 92 47052 22119 46616799
Akathisia 58.37 11.37 54 47090 7660 46631258
Neoplasm progression 58.14 11.37 100 47044 26583 46612335
Completed suicide 57.98 11.37 38 47106 145882 46493036
Neuropathy peripheral 56.58 11.37 211 46933 90682 46548236
Pleural effusion 56.23 11.37 198 46946 82754 46556164
Carbohydrate antigen 125 increased 55.48 11.37 33 47111 2377 46636541
Hospice care 54.10 11.37 44 47100 5251 46633667
Lymphadenitis 53.11 11.37 33 47111 2572 46636346
Thrombosis 51.88 11.37 149 46995 55920 46582998
Therapeutic product effect incomplete 50.43 11.37 9 47135 78144 46560774
Clostridium difficile infection 49.43 11.37 90 47054 25013 46613905
Joint swelling 49.32 11.37 57 47087 166016 46472902
Small intestinal obstruction 48.24 11.37 70 47074 16102 46622816
Injection site erythema 47.10 11.37 9 47135 74418 46564500
Therapeutic product effect decreased 46.30 11.37 13 47131 82588 46556330
Arthropathy 46.25 11.37 14 47130 84686 46554232
Abdominal pain 44.64 11.37 390 46754 229641 46409277
Gangrene 43.77 11.37 37 47107 4658 46634260
Systemic lupus erythematosus 43.17 11.37 7 47137 65173 46573745
Cytokine release syndrome 42.20 11.37 41 47103 6182 46632736
Coma 41.62 11.37 5 47139 58344 46580574
Injection site pain 41.09 11.37 29 47115 107123 46531795
Condition aggravated 39.34 11.37 122 47022 244930 46393988
Pancytopenia 39.16 11.37 180 46964 84878 46554040
Arterial occlusive disease 39.03 11.37 35 47109 4769 46634149
Colitis 38.24 11.37 103 47041 37244 46601674
Thrombocytopenia 37.90 11.37 238 46906 126343 46512575
Psoriasis 37.79 11.37 16 47128 78588 46560330
Treatment failure 37.29 11.37 24 47120 93063 46545855
Intentional overdose 34.97 11.37 11 47133 64933 46573985
Palmar-plantar erythrodysaesthesia syndrome 34.91 11.37 69 47075 20382 46618536
Pneumonitis 32.82 11.37 82 47062 28338 46610580
Blood creatine increased 32.55 11.37 31 47113 4559 46634359
Rectal cancer metastatic 30.35 11.37 11 47133 249 46638669
Injection site reaction 29.82 11.37 6 47138 47843 46591075
Failure to thrive 29.45 11.37 35 47109 6629 46632289
Pneumonia 29.32 11.37 538 46606 375782 46263136
Drug hypersensitivity 29.16 11.37 375 46769 243450 46395468
Muscle twitching 28.12 11.37 52 47092 14620 46624298
General physical health deterioration 28.05 11.37 46 47098 115723 46523195
Stomatitis 27.44 11.37 139 47005 68158 46570760
Drug interaction 27.29 11.37 109 47035 202985 46435933
Red blood cell count decreased 26.67 11.37 83 47061 32540 46606378
Psoriatic arthropathy 26.23 11.37 3 47141 36376 46602542
Taste disorder 26.19 11.37 31 47113 5847 46633071
Injection site swelling 25.25 11.37 5 47139 40322 46598596
Overdose 25.20 11.37 40 47104 101939 46536979
Mucosal inflammation 24.66 11.37 91 47053 38885 46600033
Hypokalaemia 24.18 11.37 162 46982 87862 46551056
Anaemia 24.01 11.37 377 46767 255402 46383516
Gastric disorder 23.76 11.37 70 47074 26635 46612283
Suicide attempt 23.71 11.37 13 47131 55023 46583895
Hypophagia 23.44 11.37 74 47070 29232 46609686
Cholestasis of pregnancy 22.31 11.37 14 47130 1110 46637808
Weight decreased 22.20 11.37 317 46827 210532 46428386
Dysgeusia 21.92 11.37 90 47054 40401 46598517
Lymphadenopathy 21.87 11.37 79 47065 33409 46605509
Tumour marker increased 21.55 11.37 22 47122 3519 46635399
Pyrexia 21.28 11.37 481 46663 348321 46290597
Sepsis 21.07 11.37 220 46924 135794 46503124
Blood potassium decreased 20.92 11.37 85 47059 37978 46600940
Abortion spontaneous 20.79 11.37 9 47135 43637 46595281
Skull fracture 20.05 11.37 12 47132 874 46638044
Off label use 19.99 11.37 267 46877 379574 46259344
Haemoglobin decreased 19.70 11.37 208 46936 128741 46510177
Coronary artery disease 19.50 11.37 5 47139 33747 46605171
Mobility decreased 18.84 11.37 20 47124 60574 46578344
Maternal exposure during pregnancy 18.68 11.37 48 47096 102501 46536417
Pain 18.20 11.37 356 46788 476592 46162326
Hyponatraemia 18.17 11.37 169 46975 101163 46537755
Asthma 18.14 11.37 41 47103 91501 46547417
Autoimmune nephritis 17.85 11.37 8 47136 318 46638600
Injection site pruritus 17.69 11.37 9 47135 39734 46599184
Dry skin 17.55 11.37 85 47059 40931 46597987
C-reactive protein increased 17.49 11.37 20 47124 58570 46580348
Oral pain 17.49 11.37 60 47084 24737 46614181
Acquired cystic kidney disease 17.47 11.37 5 47139 51 46638867
Cardiac failure 17.35 11.37 34 47110 79914 46559004
Hypermagnesaemia 17.10 11.37 11 47133 911 46638007
Back pain 16.90 11.37 302 46842 209737 46429181
Skin exfoliation 16.88 11.37 72 47072 32866 46606052
Morbid thoughts 16.75 11.37 9 47135 533 46638385
Drug abuse 16.50 11.37 24 47120 63384 46575534
Injection site bruising 15.96 11.37 8 47136 35628 46603290
Drug reaction with eosinophilia and systemic symptoms 15.91 11.37 5 47139 29543 46609375
Exposure during pregnancy 15.87 11.37 56 47088 108156 46530762
Laboratory test abnormal 15.86 11.37 55 47089 22792 46616126
Hypoxia 15.82 11.37 98 47046 51740 46587178
Neutropenic sepsis 15.77 11.37 37 47107 12287 46626631
Glossodynia 15.73 11.37 13 47131 44360 46594558
Pancreatic carcinoma recurrent 15.02 11.37 5 47139 87 46638831
Clostridium difficile colitis 14.97 11.37 47 47097 18506 46620412
Mental status changes 14.93 11.37 77 47067 38011 46600907
Musculoskeletal stiffness 14.85 11.37 50 47094 97943 46540975
Knee arthroplasty 14.68 11.37 3 47141 23662 46615256
Deep vein thrombosis 14.27 11.37 133 47011 79640 46559278
Lymph node pain 14.19 11.37 11 47133 1225 46637693
Lower respiratory tract infection 14.18 11.37 21 47123 55068 46583850
Hypomagnesaemia 14.17 11.37 52 47092 22158 46616760
Multiple sclerosis relapse 14.14 11.37 13 47131 42112 46596806
Dyssomnia 14.14 11.37 4 47140 39 46638879
Red blood cell sedimentation rate increased 13.99 11.37 3 47141 22886 46616032
Drug intolerance 13.97 11.37 89 47055 146960 46491958
Ovarian cancer recurrent 13.84 11.37 10 47134 1001 46637917
Fibromyalgia 13.79 11.37 10 47134 36453 46602465
Multiple sclerosis 13.70 11.37 4 47140 24787 46614131
Blood pressure fluctuation 13.39 11.37 7 47137 30441 46608477
Myocardial infarction 13.30 11.37 52 47092 97476 46541442
Product quality issue 13.20 11.37 10 47134 35638 46603280
Intentional self-injury 13.17 11.37 4 47140 24162 46614756
Red cell distribution width increased 13.16 11.37 26 47118 7678 46631240
Pericarditis 12.97 11.37 4 47140 23923 46614995
Osteonecrosis 12.76 11.37 5 47139 25739 46613179
Acute myeloid leukaemia 12.76 11.37 40 47104 15738 46623180
Plasmacytoma 12.61 11.37 14 47130 2463 46636455
Therapeutic response decreased 12.58 11.37 15 47129 43130 46595788
Infusion related reaction 12.54 11.37 56 47088 101152 46537766
Weight increased 12.52 11.37 106 47038 164367 46474551
Accidental exposure to product 12.41 11.37 3 47141 21078 46617840
Adverse drug reaction 12.39 11.37 82 47062 44280 46594638
Breast cancer metastatic 12.30 11.37 36 47108 13642 46625276
Pregnancy 12.30 11.37 6 47138 27131 46611787
Gastrointestinal injury 12.23 11.37 7 47137 469 46638449
No adverse event 12.17 11.37 10 47134 34221 46604697
Intentional product misuse 12.10 11.37 18 47126 47110 46591808
Hepatitis 11.97 11.37 9 47135 32206 46606712
Arthralgia 11.88 11.37 279 46865 364324 46274594
Loss of personal independence in daily activities 11.83 11.37 25 47119 57158 46581760
Breast cellulitis 11.69 11.37 7 47137 510 46638408
Heart rate decreased 11.61 11.37 9 47135 31714 46607204
Hepatic enzyme increased 11.54 11.37 43 47101 81744 46557174
Non-small cell lung cancer 11.47 11.37 15 47129 3129 46635789
Lymphatic disorder 11.39 11.37 6 47138 341 46638577

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 230.07 11.89 406 31056 106287 29814729
Nausea 218.57 11.89 745 30717 296212 29624804
Fatigue 162.32 11.89 715 30747 319958 29601058
Disease progression 135.95 11.89 275 31187 79599 29841417
Dehydration 116.03 11.89 338 31124 123201 29797815
Plasma cell myeloma 109.25 11.89 199 31263 53263 29867753
Malignant neoplasm progression 102.33 11.89 231 31231 72056 29848960
Vomiting 93.02 11.89 466 30996 219352 29701664
Pneumonia 87.69 11.89 625 30837 333681 29587335
Diarrhoea 78.14 11.89 608 30854 333495 29587521
Death 75.88 11.89 636 30826 356647 29564369
Decreased appetite 75.11 11.89 334 31128 149576 29771440
Drug abuse 67.08 11.89 5 31457 82067 29838949
Toxicity to various agents 65.57 11.89 54 31408 177129 29743887
Drug interaction 62.07 11.89 71 31391 199497 29721519
Full blood count decreased 52.08 11.89 73 31389 15644 29905372
Completed suicide 49.92 11.89 21 31441 99471 29821545
White blood cell count decreased 49.73 11.89 197 31265 83750 29837266
Constipation 48.72 11.89 241 31221 112665 29808351
Neuropathy peripheral 48.04 11.89 173 31289 70302 29850714
Platelet count decreased 46.83 11.89 228 31234 105901 29815115
Drug ineffective 42.94 11.89 198 31264 340189 29580827
Condition aggravated 40.73 11.89 51 31411 137815 29783201
Neutropenia 38.63 11.89 249 31213 128291 29792725
Overdose 37.43 11.89 21 31441 84316 29836700
Small intestinal obstruction 36.01 11.89 57 31405 13602 29907414
Neutrophil count decreased 35.81 11.89 112 31350 42342 29878674
Cytokine release syndrome 32.70 11.89 46 31416 9887 29911129
Failure to thrive 32.18 11.89 41 31421 8013 29913003
Back pain 30.95 11.89 199 31263 102397 29818619
Neoplasm progression 29.33 11.89 61 31401 17962 29903054
Psoriasis 28.73 11.89 5 31457 42501 29878515
Asthenia 28.45 11.89 356 31106 220934 29700082
Intentional overdose 27.77 11.89 5 31457 41476 29879540
Cardiac failure 25.52 11.89 30 31432 83388 29837628
Deep vein thrombosis 25.24 11.89 128 31334 60373 29860643
Coma 24.76 11.89 6 31456 40443 29880573
Sepsis 24.45 11.89 248 31214 146147 29774869
Rheumatoid arthritis 23.54 11.89 7 31455 41190 29879826
Suicide attempt 23.35 11.89 5 31457 36692 29884324
Hospice care 23.29 11.89 26 31436 4426 29916590
Pulmonary embolism 23.21 11.89 151 31311 77984 29843032
Rash 23.07 11.89 305 31157 191584 29729432
Bradycardia 22.94 11.89 21 31441 65505 29855511
Muscle spasms 22.86 11.89 131 31331 64707 29856309
Therapeutic product effect incomplete 22.82 11.89 4 31458 33830 29887186
Rhabdomyolysis 22.70 11.89 20 31442 63560 29857456
Ageusia 21.74 11.89 36 31426 8917 29912099
Intentional product misuse 21.50 11.89 5 31457 34662 29886354
Hyponatraemia 21.27 11.89 132 31330 67070 29853946
Coronary artery disease 21.17 11.89 13 31449 49699 29871317
Thrombosis 20.99 11.89 94 31368 42137 29878879
Product use in unapproved indication 20.97 11.89 28 31434 73665 29847351
Laboratory test abnormal 20.59 11.89 52 31410 17390 29903626
Wrong technique in product usage process 20.33 11.89 4 31458 31151 29889865
Oral pain 20.27 11.89 36 31426 9433 29911583
Spinal cord compression 20.20 11.89 22 31440 3644 29917372
Dysgeusia 19.60 11.89 64 31398 24737 29896279
Weight decreased 18.58 11.89 241 31221 150680 29770336
Adverse drug reaction 18.54 11.89 60 31402 23085 29897931
Plasma cell myeloma recurrent 17.96 11.89 20 31442 3394 29917622
C-reactive protein increased 17.65 11.89 12 31450 43461 29877555
Injection site pain 17.59 11.89 5 31457 30305 29890711
Mixed dementia 17.26 11.89 7 31455 208 29920808
Pleural effusion 16.71 11.89 134 31328 73932 29847084
Mental status changes 16.56 11.89 80 31382 36999 29884017
General physical health deterioration 16.49 11.89 52 31410 99892 29821124
Diaphragmatic rupture 16.29 11.89 4 31458 20 29920996
Drug reaction with eosinophilia and systemic symptoms 15.99 11.89 5 31457 28483 29892533
Pneumonitis 15.88 11.89 64 31398 27390 29893626
Hiccups 15.43 11.89 32 31430 9402 29911614
Myocardial infarction 15.21 11.89 74 31388 125551 29795465
Treatment failure 14.86 11.89 9 31453 34670 29886346
Limb reduction defect 14.71 11.89 6 31456 181 29920835
Clostridium difficile infection 14.57 11.89 43 31419 15740 29905276
Inferior vena caval occlusion 14.37 11.89 4 31458 35 29920981
Wrist deformity 14.15 11.89 7 31455 335 29920681
Oral candidiasis 14.11 11.89 34 31428 11037 29909979
Cholangiocarcinoma 13.78 11.89 10 31452 969 29920047
Pancytopenia 13.65 11.89 143 31319 84909 29836107
Respiratory arrest 13.39 11.89 7 31455 29251 29891765
Fluid imbalance 13.31 11.89 7 31455 381 29920635
Electrocardiogram QT prolonged 13.12 11.89 11 31451 35824 29885192
Anaemia 13.08 11.89 298 31164 207694 29713322
Hypophagia 12.99 11.89 52 31410 22184 29898832
Cholestasis 12.93 11.89 5 31457 24945 29896071
Meconium abnormal 12.76 11.89 3 31459 12 29921004
Foetal exposure during pregnancy 12.68 11.89 12 31450 36859 29884157
Immune effector cell-associated neurotoxicity syndrome 12.63 11.89 9 31453 847 29920169
Tooth disorder 12.62 11.89 29 31433 9132 29911884
Seizure 12.51 11.89 57 31405 98418 29822598
Therapeutic response decreased 12.42 11.89 5 31457 24344 29896672
Toothache 12.32 11.89 22 31440 5789 29915227
Muscular weakness 12.17 11.89 111 31351 63534 29857482

Pharmacologic Action:

SourceCodeDescription
ATC N05AB04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperazine structure
FDA CS M0016525 Phenothiazines
FDA EPC N0000175746 Phenothiazine
MeSH PA D000932 Antiemetics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37890 alpha-adrenoceptor antagonists
CHEBI has role CHEBI:48561 dopamine blocker
CHEBI has role CHEBI:48873 anticholinergika
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:65190 typical antipsychotic drug
CHEBI has role CHEBI:76779 prolyl oligopeptidase (ec 3.4.21.26) inhibitor
CHEBI has role CHEBI:131787 d2 receptor antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Schizophrenia indication 58214004 DOID:5419
Nonpsychotic Anxiety indication
Prolonged-Severe Nausea and Vomiting indication
Migraine off-label use 37796009 DOID:6364
Chemotherapy-induced nausea and vomiting off-label use 236084000
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Severe chronic ulcerative colitis contraindication 14311001
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Toxic megacolon contraindication 28536002 DOID:1770
Orthostatic hypotension contraindication 28651003
Atony of colon contraindication 29479008
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Ulcerative colitis contraindication 64766004 DOID:8577
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Extrapyramidal disease contraindication 76349003
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Hyperglycemia contraindication 80394007 DOID:4195
Hiatal hernia contraindication 84089009 DOID:12642
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Gastrointestinal obstruction contraindication 126765001
Acute disease of cardiovascular system contraindication 128487001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Myocardial dysfunction contraindication 233928007
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Angle-closure glaucoma contraindication 392291006 DOID:13550
Visual impairment contraindication 397540003
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.74 Basic
pKa2 4.74 Basic
pKa3 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.61 WOMBAT-PK IUPHAR
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.76 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.20 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.64 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.82 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.21 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.40 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.19 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.91 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 8.32 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.61 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.96 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.49 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.72 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.80 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.92 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.86 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.52 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 7.89 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.70 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.25 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 7.17 WOMBAT-PK
Histamine H1 receptor GPCR Ki 7.72 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 7.62 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 6.91 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 7.82 WOMBAT-PK
Solute carrier family 22 member 1 Transporter IC50 4.30 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.23 PDSP
D(1A) dopamine receptor GPCR Ki 7.11 DRUG MATRIX
5-hydroxytryptamine receptor 4 GPCR Ki 6.71 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 7.31 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.92 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.38 DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.77 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.02 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 7.49 CHEMBL

External reference:

IDSource
4018001 VUID
N0000146346 NUI
D00479 KEGG_DRUG
1257-78-9 SECONDARY_CAS_RN
4017999 VANDF
4018000 VANDF
4018001 VANDF
C4256066 UMLSCUI
CHEBI:8435 CHEBI
P77 PDB_CHEM_ID
DB00433 DRUGBANK_ID
CHEMBL728 ChEMBL_ID
CHEMBL1201154 ChEMBL_ID
CHEMBL1200587 ChEMBL_ID
CHEMBL1314751 ChEMBL_ID
D011346 MESH_DESCRIPTOR_UI
4917 PUBCHEM_CID
7279 IUPHAR_LIGAND_ID
699 INN_ID
YHP6YLT61T UNII
235739 RXNORM
2073 MMSL
5361 MMSL
5362 MMSL
5363 MMSL
6416 MMSL
6417 MMSL
d00355 MMSL
001478 NDDF
001479 NDDF
001480 NDDF
003466 NDDF
22827004 SNOMEDCT_US
372853006 SNOMEDCT_US
3823007 SNOMEDCT_US
395843006 SNOMEDCT_US
79129001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5105 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5110 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0440-8190 TABLET 5 mg ORAL ANDA 12 sections
Compro HUMAN PRESCRIPTION DRUG LABEL 1 0574-7226 SUPPOSITORY 25 mg RECTAL ANDA 19 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0615-2519 TABLET, FILM COATED 5 mg ORAL ANDA 12 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0615-2520 TABLET, FILM COATED 10 mg ORAL ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6135 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
Prochlorperazine HUMAN PRESCRIPTION DRUG LABEL 1 0713-0135 SUPPOSITORY 25 mg RECTAL ANDA 13 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5020 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5021 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 10544-281 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 10544-511 TABLET 5 mg ORAL ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 14789-700 INJECTION 5 mg INTRAMUSCULAR ANDA 17 sections
PROCHLORPERAZINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-327 TABLET 10 mg ORAL ANDA 10 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 21695-571 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 21695-572 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 23155-294 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
PROCHLORPERAZINE EDISYLATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-497 INJECTION 5 mg INTRAMUSCULAR ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 23155-523 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 33261-141 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 33261-550 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 42291-728 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 42291-729 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine maleate HUMAN PRESCRIPTION DRUG LABEL 1 42708-103 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 43063-353 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 43063-742 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE EDISYLATE HUMAN PRESCRIPTION DRUG LABEL 1 43066-090 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0109 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0110 TABLET, FILM COATED 5 mg ORAL ANDA 15 sections
Prochlorperazine HUMAN PRESCRIPTION DRUG LABEL 1 50090-0636 SUPPOSITORY 25 mg RECTAL ANDA 13 sections